Spago Nanomedical AB
Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well… Read more
Spago Nanomedical AB (SPAGO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.201x
Based on the latest financial reports, Spago Nanomedical AB (SPAGO) has a cash flow conversion efficiency ratio of -0.201x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.19 Million) by net assets (Skr30.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Spago Nanomedical AB - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Spago Nanomedical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Spago Nanomedical AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Spago Nanomedical AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Southern ITS International Inc
PINK:SITS
|
-0.453x |
|
Spectrumone publ AB
ST:SPEONE
|
-0.116x |
|
Kumwell Corporation Public Company Limited
BK:KUMWEL
|
0.033x |
|
AUTO NEJIMA
BC:AUTO-NEJIMA
|
N/A |
|
Comelf SA
RO:CMF
|
0.006x |
|
Streamplay Studio Ltd
AU:SP8
|
-0.037x |
|
Shiva Texyarn Limited
NSE:SHIVATEX
|
0.085x |
|
Sung Gang Asset Management Ltd
TWO:6240
|
0.004x |
Annual Cash Flow Conversion Efficiency for Spago Nanomedical AB (2011–2025)
The table below shows the annual cash flow conversion efficiency of Spago Nanomedical AB from 2011 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr30.75 Million | Skr-28.30 Million | -0.920x | +11.77% |
| 2024-12-31 | Skr33.23 Million | Skr-34.67 Million | -1.043x | +4.03% |
| 2023-12-31 | Skr41.32 Million | Skr-44.91 Million | -1.087x | -461.18% |
| 2022-12-31 | Skr197.16 Million | Skr-38.19 Million | -0.194x | -0.64% |
| 2021-12-31 | Skr184.81 Million | Skr-35.57 Million | -0.192x | -63.76% |
| 2020-12-31 | Skr159.67 Million | Skr-18.77 Million | -0.118x | +24.02% |
| 2019-12-31 | Skr137.63 Million | Skr-21.29 Million | -0.155x | -79.87% |
| 2018-12-31 | Skr122.22 Million | Skr-10.51 Million | -0.086x | -19.90% |
| 2017-12-31 | Skr107.78 Million | Skr-7.73 Million | -0.072x | +34.47% |
| 2016-12-31 | Skr71.84 Million | Skr-7.86 Million | -0.109x | -33.92% |
| 2015-12-31 | Skr65.41 Million | Skr-5.34 Million | -0.082x | +23.04% |
| 2014-12-31 | Skr56.05 Million | Skr-5.95 Million | -0.106x | +47.60% |
| 2013-12-31 | Skr38.18 Million | Skr-7.74 Million | -0.203x | -1324.77% |
| 2012-12-31 | Skr42.25 Million | Skr-601.00K | -0.014x | +33.80% |
| 2011-12-31 | Skr12.84 Million | Skr-276.00K | -0.021x | -- |